<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01023659</url>
  </required_header>
  <id_info>
    <org_study_id>068/2009</org_study_id>
    <nct_id>NCT01023659</nct_id>
  </id_info>
  <brief_title>Distribution of Bupropion and Varenicline to Increase Smoking Cessation Attempts</brief_title>
  <official_title>An Innovative Approach to Maximizing the Impact of Efficacious Pharmacotherapies on Smoking Cessation Attempts.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre for Addiction and Mental Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ontario Ministry of Health and Long Term Care</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre for Addiction and Mental Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bupropion and varenicline are indicated for smoking cessation. The objectives of this study
      are two-fold: (1) to explore the logistic feasibility of distributing bupropion and
      varenicline free of charge to treatment-seeking smokers in the province of Ontario, Canada
      and (2) to evaluate the real-world effectiveness of bupropion and varenicline treatment in
      Ontario compared to a no-drug comparison group. In an open label study, Ontario smokers who
      smoke 10 or more cigarettes per day and intend to quit smoking in the next 30 days, will
      enroll via the study website, visit their physician to receive a prescription for bupropion
      or varenicline for 12 weeks or neither if they so choose, forming the no-drug comparison
      group. All participants will receive weekly motivational emails for 12 weeks. Abstinence
      measures will be taken at 4, 8 and 12 weeks and at 6 and 12 months. The proportion of
      eligible participants who were able to confirm an appointment with a physician to receive the
      prescription will be also measured.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bupropion and varenicline are effective pharmacotherapies for smoking cessation, but their
      population level impact is limited by a combination of factors. Both bupropion and
      varenicline are only available through prescription, however smoking cessation clinics are
      few in number and only about 25% of smokers receive information on smoking cessation aids
      from their healthcare provider. Mass distribution approaches, bypassing clinics and
      physicians, have been successful for nicotine replacement therapy in many jurisdictions,
      including Ontario. However, bupropion and varenicline have the potential to make a greater
      impact given their superior results from the clinical trials. Bupropion and varenicline
      present a unique challenge as they are prescribed medications, therefore we have proposed a
      variant of the mass distribution method to test whether it is practical to distribute them to
      a large number of people over a expansive geographic area (i.e., Ontario).

      We hypothesize that engaging smokers with the opportunity to receive free bupropion or
      varenicline, to initiate an appointment with their physician to obtain a prescription that
      would be filled and mailed to the smoker from a central pharmacy would be a logistically
      feasible approach to reach high number of smokers from a wide geographic area. Our second
      hypothesis is that consistent with the results from clinical studies, in the general
      population varenicline would be associated with a higher abstinence rate than bupropion, and
      both varenicline and bupropion groups would achieve higher abstinence rates than those making
      quit attempts without any pharmacotherapy aid.

      This is an open label, proof-of-concept study, wherein 2000 eligible participants will have
      the opportunity to receive bupropion (Zyban®) or varenicline (Champix®) for 12 weeks in
      conjunction with weekly motivational emails. Eligible participants will discuss with their
      doctor which of the two medications is appropriate for them to use as smoking cessation aid.
      It is also possible that the participant and his/her doctor may decide not to pursue smoking
      cessation using either of these medications. These participants will form a third
      intervention group, receiving only the weekly motivational emails. All participants will set
      a quit date of their choosing, but those receiving medication will set a quit date 7 days
      after starting the medication. The participants will enroll in the study via the study's
      website, at which time they will read the consent form, answer the eligibility questions and
      complete the baseline questionnaire. Data related to the outcome measures and adverse events
      will be collected at 4, 8 and 12 weeks after the start of treatment and at 6 and 12 months
      after the end of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>7-day Point Prevalence of Abstinence</measure>
    <time_frame>6-month</time_frame>
    <description>7-day point prevalence of abstinence was assessed by the question &quot;Have you had a cigarette, even a puff, in the past 7 days?&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Eligible Participants Who Were Able to Attend an Appointment With a Physician</measure>
    <time_frame>End of Treatment</time_frame>
    <description>Proportion of eligible participants who were able to attend an appointment with a physician to have the prescription signed</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">893</enrollment>
  <condition>Tobacco Use Disorder</condition>
  <condition>Smoking</condition>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Bupropion + motivational emails</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>participants receive Zyban (300mg/day) plus weekly motivational emails for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Varenicline + motivational emails</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>participants receive Champix (2mg/day) plus weekly motivational emails for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Motivational emails</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>participants receive weekly motivational emails for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupropion</intervention_name>
    <description>bupropion, 150 mg twice daily plus weekly motivational emails for 12 weeks</description>
    <arm_group_label>Bupropion + motivational emails</arm_group_label>
    <other_name>Zyban</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>varenicline</intervention_name>
    <description>varenicline, 1 mg twice daily plus weekly motivational emails for 12 weeks</description>
    <arm_group_label>Varenicline + motivational emails</arm_group_label>
    <other_name>Champix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>motivational emails</intervention_name>
    <description>brief motivational emails, sent weekly for 12 weeks</description>
    <arm_group_label>Bupropion + motivational emails</arm_group_label>
    <arm_group_label>Varenicline + motivational emails</arm_group_label>
    <arm_group_label>Motivational emails</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female, at least 18 years of age, resident of Ontario, smoke at least 10
             cigarettes per day, had smoked daily for at least the past 3 months, had smoked at
             least 100 cigarettes in their lifetime and intended to quit smoking in the next 30
             days.

        Exclusion Criteria:

          -  history of brain injury or seizure(s); pregnancy, lactation or risk of becoming
             pregnant; allergy or sensitivity to bupropion or varenicline; current use of monoamine
             oxidase inhibitors (MAOIs), thioridazine, varenicline or buproprion; severe liver
             impairment; or history of anorexia and /or bulimina.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Selby, MD, MHSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Addiction and Mental Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Addiction and Mental Health</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 1P7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Selby P, Hussain S, Voci S, Zawertailo L. Empowering smokers with a web-assisted tobacco intervention to use prescription smoking cessation medications: a feasibility trial. Implement Sci. 2015 Oct 1;10:139. doi: 10.1186/s13012-015-0329-7.</citation>
    <PMID>26429100</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2009</study_first_submitted>
  <study_first_submitted_qc>December 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2009</study_first_posted>
  <results_first_submitted>February 14, 2013</results_first_submitted>
  <results_first_submitted_qc>February 14, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 15, 2013</results_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre for Addiction and Mental Health</investigator_affiliation>
    <investigator_full_name>Dr. Peter Selby</investigator_full_name>
    <investigator_title>Clinical Director, Addictions Program</investigator_title>
  </responsible_party>
  <keyword>Smoking cessation</keyword>
  <keyword>Bupropion</keyword>
  <keyword>Varenicline</keyword>
  <keyword>Population-level</keyword>
  <keyword>Mass distribution</keyword>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants visited the study website, provided consent and completed an on-line assessment. Eligible participants received a personalized script to take to their physician, who could prescribe varenicline or bupropion for 12 weeks, or neither.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Bupropion + Motivational Emails</title>
          <description>participants receive Zyban (300mg/day) plus weekly motivational emails for 12 weeks.
bupropion : bupropion, 150 mg twice daily plus weekly motivational emails for 12 weeks
motivational emails : brief motivational emails, sent weekly for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Motivational Emails</title>
          <description>participants receive weekly motivational emails for 12 weeks.
motivational emails : brief motivational emails, sent weekly for 12 weeks</description>
        </group>
        <group group_id="P3">
          <title>Varenicline + Motivational Emails</title>
          <description>participants receive Champix (2mg/day) plus weekly motivational emails for 12 weeks.
motivational emails : brief motivational emails, sent weekly for 12 weeks
varenicline : varenicline, 1 mg twice daily plus weekly motivational emails for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="258"/>
                <participants group_id="P2" count="365"/>
                <participants group_id="P3" count="264"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="185"/>
                <participants group_id="P2" count="137"/>
                <participants group_id="P3" count="165"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="228"/>
                <participants group_id="P3" count="99"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="228"/>
                <participants group_id="P3" count="99"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bupropion + Motivational Emails</title>
          <description>participants receive Zyban (300mg/day) plus weekly motivational emails for 12 weeks.
bupropion : bupropion, 150 mg twice daily plus weekly motivational emails for 12 weeks
motivational emails : brief motivational emails, sent weekly for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Motivational Emails</title>
          <description>participants receive weekly motivational emails for 12 weeks.
motivational emails : brief motivational emails, sent weekly for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Varenicline + Motivational Emails</title>
          <description>participants receive Champix (2mg/day) plus weekly motivational emails for 12 weeks.
motivational emails : brief motivational emails, sent weekly for 12 weeks
varenicline : varenicline, 1 mg twice daily plus weekly motivational emails for 12 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="258"/>
            <count group_id="B2" value="365"/>
            <count group_id="B3" value="264"/>
            <count group_id="B4" value="887"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.4" spread="12.2"/>
                    <measurement group_id="B2" value="38.6" spread="12.0"/>
                    <measurement group_id="B3" value="44.0" spread="12.8"/>
                    <measurement group_id="B4" value="41.9" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="196"/>
                    <measurement group_id="B3" value="157"/>
                    <measurement group_id="B4" value="503"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="169"/>
                    <measurement group_id="B3" value="107"/>
                    <measurement group_id="B4" value="384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="258"/>
                    <measurement group_id="B2" value="365"/>
                    <measurement group_id="B3" value="264"/>
                    <measurement group_id="B4" value="887"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education level- less than high school diploma</title>
          <description>Number of participants with less than high school diploma</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Annual household income:$20,000 or less</title>
          <description>number participants with annual income equal or less than $20,000</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="164"/>
                    <measurement group_id="B3" value="93"/>
                    <measurement group_id="B4" value="373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title># Participants currently employed</title>
          <description>Number of participants who report being employed</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="198"/>
                    <measurement group_id="B3" value="138"/>
                    <measurement group_id="B4" value="472"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title># cigarettes smoked per day</title>
          <description># participants in cpd smoking category</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>10-19 cpd</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="131"/>
                    <measurement group_id="B3" value="87"/>
                    <measurement group_id="B4" value="299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20-29 cpd</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="186"/>
                    <measurement group_id="B3" value="138"/>
                    <measurement group_id="B4" value="457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 + cpd</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title># participants who smoke first morning cigarette within 5 minutes</title>
          <description># participants who report smoking first morning cigarette within 5 minutes after waking-up.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="186"/>
                    <measurement group_id="B3" value="118"/>
                    <measurement group_id="B4" value="426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Years since started smoking daily</title>
          <description>Mean (SD) years since started smoking daily</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.7" spread="12.1"/>
                    <measurement group_id="B2" value="24.2" spread="12.0"/>
                    <measurement group_id="B3" value="30.0" spread="12.7"/>
                    <measurement group_id="B4" value="27.5" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title># participants with less than 3 quit attempts</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="220"/>
                    <measurement group_id="B3" value="118"/>
                    <measurement group_id="B4" value="478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Confidence in Quitting</title>
          <description>10 point scale from: 1- Very little confidence quitting ...to.. 10-Very confident in quitting</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.8" spread="2.2"/>
                    <measurement group_id="B2" value="7.5" spread="2.1"/>
                    <measurement group_id="B3" value="7.8" spread="2.0"/>
                    <measurement group_id="B4" value="7.7" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title># Participants who report previous use of smoking cessation medication</title>
          <description># participants who report previous use of medication for smoking cessation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="186"/>
                    <measurement group_id="B3" value="142"/>
                    <measurement group_id="B4" value="470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title># participants with longest period of abstinence from smoking- less than 1 week</title>
          <description># participants who report longest period of abstinence from smoking of less than 1 week</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>less than 1 week</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="264"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1 week or more</title>
                  <measurement_list>
                    <measurement group_id="B1" value="183"/>
                    <measurement group_id="B2" value="250"/>
                    <measurement group_id="B3" value="190"/>
                    <measurement group_id="B4" value="623"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Participants who report all or most of my friends smoke</title>
          <description>self report: Proportion of friends that smoke - all or most of my friends smoke</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="180"/>
                    <measurement group_id="B3" value="84"/>
                    <measurement group_id="B4" value="344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lives with other smoker(s)</title>
          <description>Yes- lives with other smokers</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="219"/>
                    <measurement group_id="B3" value="139"/>
                    <measurement group_id="B4" value="498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of drug or alcohol problem</title>
          <description>Self report history of alcohol or drug problem</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>7-day Point Prevalence of Abstinence</title>
        <description>7-day point prevalence of abstinence was assessed by the question &quot;Have you had a cigarette, even a puff, in the past 7 days?&quot;</description>
        <time_frame>6-month</time_frame>
        <population>Number of eligible participants who either received bupropion + motivational emails, varenicline + motivational emails or motivational emails alone (because they either did not attend a physician visit or their physician decided not to prescribe them bupropion or varenicline)</population>
        <group_list>
          <group group_id="O1">
            <title>Bupropion + Motivational Emails</title>
            <description>participants receive Zyban (300mg/day) plus weekly motivational emails for 12 weeks.
bupropion : bupropion, 150 mg twice daily plus weekly motivational emails for 12 weeks
motivational emails : brief motivational emails, sent weekly for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Motivational Emails</title>
            <description>participants receive weekly motivational emails for 12 weeks.
motivational emails : brief motivational emails, sent weekly for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Varenicline + Motivational Emails</title>
            <description>participants receive Champix (2mg/day) plus weekly motivational emails for 12 weeks.
motivational emails : brief motivational emails, sent weekly for 12 weeks
varenicline : varenicline, 1 mg twice daily plus weekly motivational emails for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>7-day Point Prevalence of Abstinence</title>
          <description>7-day point prevalence of abstinence was assessed by the question &quot;Have you had a cigarette, even a puff, in the past 7 days?&quot;</description>
          <population>Number of eligible participants who either received bupropion + motivational emails, varenicline + motivational emails or motivational emails alone (because they either did not attend a physician visit or their physician decided not to prescribe them bupropion or varenicline)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Eligible Participants Who Were Able to Attend an Appointment With a Physician</title>
        <description>Proportion of eligible participants who were able to attend an appointment with a physician to have the prescription signed</description>
        <time_frame>End of Treatment</time_frame>
        <population>total number of eligible participants in study</population>
        <group_list>
          <group group_id="O1">
            <title>All Eligible Participants</title>
            <description>All participants who were eligible to receive medication</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Eligible Participants Who Were Able to Attend an Appointment With a Physician</title>
          <description>Proportion of eligible participants who were able to attend an appointment with a physician to have the prescription signed</description>
          <population>total number of eligible participants in study</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="893"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="588"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Serious and other [non-serious] adverse events were not collected or assessed as part of the study</desc>
      <group_list>
        <group group_id="E1">
          <title>Bupropion + Motivational Emails</title>
          <description>participants receive Zyban (300mg/day) plus weekly motivational emails for 12 weeks.
bupropion : bupropion, 150 mg twice daily plus weekly motivational emails for 12 weeks
motivational emails : brief motivational emails, sent weekly for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Motivational Emails</title>
          <description>participants receive weekly motivational emails for 12 weeks.
motivational emails : brief motivational emails, sent weekly for 12 weeks</description>
        </group>
        <group group_id="E3">
          <title>Varenicline + Motivational Emails</title>
          <description>participants receive Champix (2mg/day) plus weekly motivational emails for 12 weeks.
motivational emails : brief motivational emails, sent weekly for 12 weeks
varenicline : varenicline, 1 mg twice daily plus weekly motivational emails for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Peter Selby</name_or_title>
      <organization>Centre for Addiction and Mental Heatlh</organization>
      <phone>416-535-8501 ext 74946</phone>
      <email>peter.selby@camh.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

